Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Park Language May Be On The Way In FDA Warnings To OTC Firms

This article was originally published in The Tan Sheet

Executive Summary

Food and drug attorney Frederick Stearns predicts FDA soon will include Park Doctrine language threatening criminal charges against individuals at OTC firms, in part because the language appears in letters to dietary supplement firms. The agency also is sending more GMP warning letters to drug companies.

You may also be interested in...



American Conference Institute In Brief

GMP problems could yield Park Doctrine cases; POM Wonderful decision missed FTC attorneys’ goal; supplement industry needs Durbin’s help; more news from the American Conference Institute’s June 26-27 legal, regulatory and compliance forum on dietary supplements.

FDA Posts Criteria For Targeting Executives As Responsible Officers

FDA publishes criteria for filing criminal misdemeanor charges against executives from firms that break food and drug laws almost a year after the agency signaled its intent to pursue such cases.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel